REVB news

Latest 2 stories · newest Nov 5, 2026

REVB

Revelation Biosciences reports $9.1M cash as Q3 '26 net loss expands

Revelation Biosciences reported a wider net loss in Q3 2026 to $3.3 million despite reducing operating cash burn. The company asserts its cash runway will extend into Q2 2027 and announced plans to select a CRO for a new Gemini study.

Earnings Nov 5, 2026 sentiment -0.40 SEC filing ↗

REVB

Revelation Biosciences files 8-K exhibit with limited financial disclosure details

Revelation Biosciences submitted an SEC 8-K filing with an exhibit document containing minimal substantive financial or operational information. Without specific business developments or material events disclosed, the market impact remains unclear pending full filing review.

Other Jun 1, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same REVB feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/REVB/newsSTART FREE